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vents cerebral ischemia-reperfusion injury. However, the effect of peripheral administration of
serofendic acid on cerebral ischemia-reperfusion injury has not been examined. In the present
study, we investigated the effect of intravenous administration of serofendic acid against
cerebral ischemia-reperfusion injury using transient middle cerebral artery occlusion model
rats. Serofendic acid (10 mg/kg) administrated three times, including 30 min before the onset
of ischemia, just after the onset of ischemia and just before reperfusion reduced the infarct
volume and improved the neurological dysfunction induced by ischemia-reperfusion without
affecting regional cerebral blood ﬂow or physiological parameters. However, there were no
protective effects when serofendic acid (30 mg/kg) was only administered once at 30min
before the onset of ischemia, just after the onset of ischemia, or just before reperfusion. Our
results reveal the importance of maintaining the blood concentration of serofendic acid for
preventing cerebral ischemia-reperfusion injury.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Elsevier B.V.
3
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Cerebral ischemia-reperfusion causes injury to brain tissues,
including neurons, glial cells, and cerebral blood vessels,
resulting in their dysfunction. Numerous studies have
revealed the possible factors that cause cell damage and thetherapeutic targets of cerebral ischemia-reperfusion injury.
For instance, massive release of glutamate into the extra-
cellular space, induction of oxidative stress, and generation of
proinﬂammatory cytokines occur during or after ischemia.
Suppression of these events attenuates ischemic insults
(Lakhan et al., 2009; Mehta et al., 2007; Nakka et al., 2008;
b r a i n r e s e a r c h 1 5 3 2 ( 2 0 1 3 ) 9 9 – 1 0 5100Park et al., 1988; Peters et al., 1998; Tuttolomondo et al., 2009).
There are two regions in an ischemic brain: the ischemic core
and the penumbra. In the ischemic core region, neurons and
glial cells suffer severe injury characterized by necrosis and
their function is irreversibly impaired during the acute phase
of ischemia-reperfusion. In the penumbra region, cell insults
are moderate and cell death due to apoptosis progresses for
several days (Ueda and Fujita, 2004). Research into agent
intervention to save cells from cell death in the penumbra
region is ongoing (Barone, 2009; Kaushal and Schlichter,
2008). We previously found a neuroprotective substance,
serofendic acid, in a lipophilic extract of fetal calf serum.
Serofendic acid is 15-hydroxy-17-methylsulﬁnylatisan-19-oic
acid and a sulfur-containing atisan-type diterpenoid (Kume
et al., 2002). It is a low-molecular-weight (mw 382) compound
and exhibits potent protective effects on neurotoxicity
induced by glutamate, NO, and oxidative stress without
inhibiting glutamate receptors in cultured cortical, striatal,
and spinal cord neurons (Kume et al., 2005, 2006; Osakada
et al., 2004; Taguchi et al., 2003). Moreover, in cardiac
myocytes, serofendic acid suppresses cell death induced byThree admin
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Fig. 1 – Representative images showing the effects of three admi
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into coronal sections for TTC staining. Serofendic acid was adm
ischemia, and just before reperfusion respectively.oxidative stress (Akao et al., 2007; Takeda et al., 2006). While
the mechanism of protection remains unclear, it has been
demonstrated that serofendic acid inhibits the generation of
hydroxyl radicals and prevents mitochondrial membrane
depolarization and caspase-3 activation (Kume et al., 2006;
Osakada et al., 2004; Taguchi et al., 2003). We have previously
reported the protective effect of serofendic acid on ischemia-
reperfusion injury induced by transient middle cerebral
artery occlusion (tMCAo) in rats. Intracerebroventricular
administration of serofendic acid reduced the infarct volume,
particularly in the cortex, and improved neurological deﬁcit
scores (Nakamura et al., 2008). However, we previously
reported that serofendic acid had a very low brain-to-
plasma value (0.021), as passive transport of serofendic acid
hardly occurs because of the existence of the carboxylic group
(Terauchi et al., 2007). Thus, there are no reports of the effect
of peripheral administration of serofendic acid on cerebral
ischemia-reperfusion injury. Whereas, serofendic acid enters
into the brain in some degree in intravenous administration
(Terauchi et al., 2007) and it protects against cerebral
ischemia-reperfusion injury at low concentration in the brainistrations
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b r a i n r e s e a r c h 1 5 3 2 ( 2 0 1 3 ) 9 9 – 1 0 5 101(Nakamura et al., 2008). Therefore, we investigated the effect
of serofendic acid administrated intravenously on ischemia-
reperfusion injury induced by tMCAo in rats.0
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Fig. 2 – Dose-dependent effect of three administrations of
serofendic acid on infarct volume (A) and neurological deﬁcit
scores (B) after 48 h of reperfusion in transient MCA occlusion.
Serofendic acid was administered intravenously 30min before
ischemia, just after ischemia, and just before reperfusion. The
numbers in the columns indicate the number of experiments
performed. *Po0.05 and **Po0.01, compared with vehicle.2. Results
2.1. Intravenously administered serofendic acid reduces
infarct volume and neurological deﬁcit induced by transient
middle cerebral artery occlusion (MCAo) in a dose-dependent
manner
We examined the protective effect of multiple intravenous
administration of serofendic acid because blood level of
serofendic acid is immediately decreased (Terauchi et al.,
2007). As a multiple administration, we utilized three times
administration of serofendic acid at 30 min before the onset
of ischemia, just (within 5 min) after the onset of ischemia,
and just (whithin 5 min) before reperfusion. Three times
administration of serofendic acid (10 mg/kg) reduced infarct
volume (Fig. 1).
Next, we examined the dose-dependent effect of serofen-
dic acid on infarct volume. Three times administration of
serofendic acid (1–10 mg/kg) reduced infarct volume in a
dose-dependent manner (Fig. 2A). We examined the func-
tional recovery by three times administration of serofendic
acid with the evaluation of neurological deﬁcit scores. Ser-
ofendic acid (1–10 mg/kg) improved neurological deﬁcit scores
in a dose-dependent manner (Fig. 2B). It is suggested that
necrotic cell death occurs at ischemic core region and
apoptotic cell death occurs at ischemic penumbra region
(Ueda and Fujita, 2004). So, we examined the infarct volume
limitation effect of serofendic acid at ischemic core (striatum)
and penumbra (cerebral cortex) region to suggest that ser-
ofendic acid protects from which type of cell death. Serofen-
dic acid signiﬁcantly reduced the infarct volume at cerebral
cortex, but did not affect the infarct volume at striatum
(Fig. 3).
2.2. Intravenously administered serofendic acid does not
effect regional cerebral blood ﬂow
Cerebral blood ﬂow is a crucial factor for ischemic insults.
Thus, we further examined the effect of serofendic acid on
regional cerebral blood ﬂow (rCBF) at just after ischemia, just
before reperfusion, and just after reperfusion. Serofendic acid
did not regulate rCBF at ischemic and reperfusion phase
(Table 1).
2.3. Intravenously administered serofendic acid does not
affect physiological parameters
Several physiological parameters (pH, PaO2, PaCO2, and glu-
cose content of arterial blood) inﬂuence the degree of cerebral
damages induced ischemia-reperfusion. Thus, we investigated
the effect of serofendic acid on physiological parameters
30min after each of the three administrations. We found no
effect of serofendic acid on any physiological parameters in
the sham-operated and ischemia-reperfusion-operated groups
(Table 2).2.4. Single intravenous administration of serofendic acid
does not reduce infarct volume and neurological deﬁcit induced
by transient middle cerebral artery occlusion
Next, we administered a single dose of serofendic acid (30mg/kg)
at 30min before ischemia, just after ischemia, or just before
reperfusion in order to determine whether three administrations
are necessary to achieve protective effects. No single adminis-
tration of serofendic acid showed any protective effect on infarct
volume or neurological deﬁcit score (Fig. 4).3. Discussion
The major ﬁnding of this study is that serofendic acid,
administered intravenously, has the protective effect on the
b r a i n r e s e a r c h 1 5 3 2 ( 2 0 1 3 ) 9 9 – 1 0 5102injury induced by cerebral ischemia-reperfusion. We have
previously reported that intracerebroventricular administra-
tion of serofendic acid protects against ischemic injury in
tMCAo model rats (Nakamura et al., 2008). However, it was
not sufﬁcient for considering about clinical application of
serofendic acid because of the poor permeability into brain in
case of peripheral administration. In the present study, we
showed that intravenous administration of serofendic acid,
when administrated three times, reduced infarct volume and
improved neurological function without affecting rCBF or
physiological parameters.
As shown in Fig. 3, serofendic acid reduced the infarct
volume in the cortex but not in striatum, similar to our previous
results for intracerebroventricular administration (Nakamura
et al., 2008). We previously reported that serofendic acid inhibits0
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Fig. 3 – Effect of three administrations of serofendic acid
(10 mg/kg) on infarct volume in the striatum or cortex after
48 h of reperfusion in transient MCA occlusion. Serofendic
acid was administered intravenously 30 min before
ischemia, just after ischemia, and just before reperfusion.
The numbers in the columns indicate the number of
experiments performed. **Po0.01, compared with vehicle.
Table 1 – Regional cerebral blood ﬂow (rCBF)
Vehicle
Number 10
rCBF (%)
Just after ischemia 33.271.6
Just before reperfusion 33.072.0
Just after reperfusion 97.573.9
Serofendic acid was administered intravenously 30
just before reperfusion. There were no statistically
groups. Fdrug¼1.67.caspase-3 activation in vitro (Kume et al., 2006) and several
reports showed that inhibition of caspases attenuates apoptosis
in the penumbra in tMCAo models (Lei et al., 2004; Sung et al.,
2007). Thus, the inhibition of activation of caspases-3 is sug-
gested to play a central role in the protective effect of serofendic
acid in the cortex.
We previously reported that serofendic acid affords pro-
tection against reactive oxygen species (ROS)-induced oxida-
tive injury (Osakada et al., 2004). Many anti-oxidative
substances have been shown to have protective effects
against cerebral ischemia-reperfusion injury (Amemiya
et al., 2005; Connell et al., 2011; Shih et al., 2005). Taken
together, we can assume that the anti-oxidative properties of
serofendic acid contribute its protective effect against cere-
bral ischemia-reperfusion injury.
Based on our previous reports regarding the permeability
of serofendic acid into the brain (Terauchi et al., 2007), we
estimated that the brain dose of serofendic acid in normal
condition with intravenous treatment of 10 mg/kg was
equivalent to 2.1 nmol. Our previous report showed that
10 nmol of serofendic acid with intracerebroventricular treat-
ment was required to exhibit the protective effect on
ischemic neuronal damage (Nakamura et al., 2008). Thus,
we predicted that serofendic acid may fail to protect the brain
from ischemia-reperfusion injury when administered intra-
venously. Contrary to our expectations, intravenous admin-
istration of serofendic acid exerted protective effects on
cerebral ischemia-reperfusion injury without affecting rCBF
and physiological parameters. While serofendic acid has a
relatively low ability to penetrate the blood brain barrier
(BBB), it can be detected in the brain after intravenous
administration (Terauchi et al., 2007). We assume that its
low concentration in the brain is able to exert a protective
effect since a low dose (10–30 nmol) of intracerebroventricu-
larly administered serofendic acid was effective on cerebral
ischemia-reperfusion injury (Nakamura et al., 2008). Thus,
the small amount of serofendic acid that penetrates into the
brain tissue may be sufﬁcient to protect cells from ischemia-
reperfusion injury.
Since cerebral ischemia-reperfusion injury leads to the
breakdown of BBB, molecules that cannot inﬁltrate the BBB in
normal conditions may be able to do so more in case of
cerebral ischemia-reperfusion injury (Haile et al., 2010;
Michalski et al., 2010). It is possible that serofendic acidin the serofendic acid-treated groups.
Treatment (three administrations)
Serofendic acid (mg/kg)
1 3 10
10 10 11
30.172.4 27.072.0 32.371.6
26.672.3 27.072.8 33.772.2
99.874.1 107.575.1 104.875.0
min before ischemia, just after ischemia, and
signiﬁcant differences at any time among the
Table 2 – Physiological parameters in the serofendic acid- and vehicle-treated groups.
Sham Ischemia-reperfusion
Treatment (three administrations) Treatment (three administrations)
Vehicle Serofendic acid (10 mg/kg) Vehicle Serofendic acid (10 mg/kg)
Number 5 5 5 5
10 min before ﬁrst administration of drug
pH 7.4670.01 7.4570.01 7.4770.01 7.4770.03
PaO2 (mmHg) 8173 8473 8173 8273
PaCO2 (mmHg) 3871 4172 4171 3973
Glucose (mg/dl) 18477 17577 18374 16477
30 min after ﬁrst administration of drug
pH 7.3970.04 7.4770.02 7.4470.01 7.4470.03
PaO2 (mmHg) 7473 7973 8173 7573
PaCO2 (mmHg) 4172 4173 4172 4373
Glucose (mg/dl) 175714 15978 15175 15476
30 min after second administration of drug
pH 7.4370.01 7.4470.01 7.4370.01 7.4770.02
PaO2 (mmHg) 6872 6971 6972 7372
PaCO2 (mmHg) 4471 4472 4272 4271
Glucose (mg/dl) 15979 15575 14379 15373
30 min after third administration of drug
pH 7.4470.01 7.4570.01 7.4270.02 7.4570.02
PaO2 (mmHg) 6172 6673 6774 5973
PaCO2 (mmHg) 4272 4572 4874 4672
Glucose (mg/dl) 14478 15075 145711 15177
Serofendic acid was administered intravenously 30 min before ischemia, just after ischemia, and just before reperfusion. There were no
statistically signiﬁcant differences in any parameters at any time among the groups.
b r a i n r e s e a r c h 1 5 3 2 ( 2 0 1 3 ) 9 9 – 1 0 5 103may pass through the injured BBB more easily than under
normal conditions. Further studies are needed to determine
whether BBB disruption is required for a sufﬁcient amount of
serofendic acid to pass through.
In the present study, three administrations of serofendic
acid exerted protective effects on cerebral ischemia-
reperfusion injury, whereas single administration did not
protect from ischemia-reperfusion injury. In our previous
study, serofendic acid exhibited a high clearance value
when administered intravenously (T1/2: 0.65 h) (Terauchi
et al., 2007). Thus, the protective effects from three adminis-
trations of serofendic acid are not because of the total dose
(30 mg/kg) but because of persistent blood concentrations.
We showed that protective effect of serofendic acid admini-
strated intravenously requires pretreatment before ischemia,
whereas serofendic acid intracerebroventricularly adminis-
tered at 30 min after the onset of ischemia protected brain
from ischemia-reperfusion injury (Nakamura et al., 2008).
This difference may have occurred owing to the poor ability
of serofendic acid to penetrate BBB or be retained in the brain
tissue. Regulation of pharmacokinetics of serofendic acid
may enable serofendic acid administered intravenously after
the onset of ischemia to exert protective effect on ischemia-
reperfusion injury.
In conclusion, our study shows that intravenous adminis-
tration of serofendic acid has protective effects on cerebral
ischemia-reperfusion injury induced by transient middle cere-
bral artery occlusion in rats. Our results offer the importantﬁndings for development of therapeutic agents of cerebral
ischemia-reperfusion injury.4. Experimental procedure
4.1. Animals
Experiments were performed using 10-week-old male Sprague-
Dawley rats weighing 300–330 g, which were purchased from
Nihon SLC (Shizuoka, Japan). The animals were treated in
accordance with the guidelines of the Kyoto University Animal
Experimentation Committee and the Japanese Pharmacologi-
cal Society.
4.2. Surgical procedure and drug administration
The middle cerebral artery was occluded for 90 min and then
reperfused for 48 h using the intraluminal suture technique,
which was modiﬁed as described previously (Nagasawa and
Kogure, 1989). Brieﬂy, rats were anesthetized with halothane
(3.5% for induction, 1% for maintenance, Takeda Pharmaceu-
tical, Co., Ltd., Osaka, Japan) during surgery. After median
incision of the neck skin, the left common and external carotid
arteries were carefully exposed and ligated. A 19-mm length of
silicon-coated 4-0 nylon surgical thread was transiently
inserted into the left internal carotid artery for 90min to
occlude the left middle cerebral artery at its origin. While the
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Fig. 4 – Effect of single administration of serofendic acid
(30 mg/kg) on infarct volume (A) and neurological deﬁcit
scores (B) after 48 h of reperfusion in transient MCA
occlusion. Serofendic acid was administered intravenously
30 min before ischemia, just after ischemia, or just before
reperfusion. The numbers in the columns indicate the
number of experiments performed.
b r a i n r e s e a r c h 1 5 3 2 ( 2 0 1 3 ) 9 9 – 1 0 5104animals were anesthetized, rectal temperatures were main-
tained at 37.070.5 1C. Sham-operated animals underwent the
same procedure except for a transient occlusion. Animals were
randomly divided into serofendic acid- and vehicle-treated
groups. Serofendic acid was dissolved in 1 N NaOH and diluted
with 50mM PBS. Rats were intravenously administered serofen-
dic acid or vehicle either once or three times at 30min before the
onset of ischemia, just (within 5min) after the onset of ischemia,
and just (within 5min) before reperfusion. Serofendic acid wassynthesized as described previously (Terauchi et al., 2007) and
supplied by Eisai Co., Ltd. (Tsukuba, Japan).
4.3. Evaluation of infarct volume by TTC staining
Infarct volume was evaluated as described previously (Zhao
et al., 2005). Brieﬂy, rats were anesthetized with pentobarbital
(80 mg/kg, i.p.) and perfused with cold PBS through the left
ventricle. The brain was quickly removed and sliced into
eight 2-mm thick coronal sections using a brain slicer (Brain
science Idea, Co., Ltd., Osaka, Japan). The slices were
immersed in a saline solution containing 2% 2,3,5-triphenyl-
tetrazolium chloride (TTC, Nakalai Tesque, Kyoto, Japan) and
ﬁxed by 10% neutral formalin isotonic ﬂuid. The sections
were quantiﬁed using Image J software. Total infarct volume
was determined by summing the infarct area of the eight
sections. The infarct volume in the cortex or the striatum was
determined by summing the sections numbered 3, 4, and 5 or
3 and 4, respectively. Results were calculated as a percentage
of the ipsilateral to the contralateral hemispheric volume.
4.4. Assessment of neurological deﬁcit scores
Neurological symptoms after 48 h of reperfusion were assessed
using neurological deﬁcit scores (grade 0–4), which were mod-
iﬁed as described previously (Murakami et al., 1998). Rats were
suspended by the tail, and forelimb ﬂexion and body twisting
were evaluated as 0 (no observable neurological deﬁcit), 1 (failed
to extend right forepaw), 2 (circled to the right), 3 (failed to move
the right forepaw), or 4 (could not walk spontaneously).
4.5. Measurement of regional blood ﬂow
Regional cerebral blood ﬂow in the left middle cerebral artery
territory (7 mm lateral and 1 mm posterior to the bregma)
was measured at each time point (before and after the onset
of ischemia and at reperfusion) using Laser-Doppler ﬂowme-
try FLO-N1 (Omegawave Inc., Tokyo, Japan) as described
previously (Amemiya et al., 2005).
4.6. Measurement of physiological parameters
Blood gases, pH, PaO2, PaCO2, and glucose content were
measured at 15 min before the ﬁrst administration and
30 min after each administration using CG8þ cartridges in a
portable blood analyzer (i-STAT 300F, Fuso Pharmaceutical
Industries, Ltd., Osaka, Japan).
4.7. Statistical analyses
Data are expressed as means7S.E.M. Statistical analyses
were performed using GraphPad Instat (GraphPad Software,
San Diego, USA). The dose-dependent effects of three admin-
istrations of serofendic acid on infarct volume in the cortex or
the striatum were analyzed using one-way analysis of var-
iance followed by Dunnet's two-tailed test. Kruskal–Wallis
test was used for neurological deﬁcit scores. Regional cerebral
blood ﬂow and physiological parameters were analyzed using
two-way analysis of variance. Statistical signiﬁcance was
deﬁned as a probability value of less than 5%.
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